Intra Cranial EEG Activity During Dexmedetomidine Sedation
This study is not yet open for participant recruitment.
Verified July 2012 by University Health Network, Toronto
Sponsor:
University Health Network, Toronto
Information provided by (Responsible Party):
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT01648959
First received: July 13, 2012
Last updated: July 23, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Various parts of the brain are sensitive to various anesthetics.We like to study the effect of dexmedetomidine on the different parts of the brain in patients who are coming for DBS electrode removal under sedation.
| Condition |
|---|
|
EEG Effect of Dexmedetomidine on the Cortical and Subcortical Structures |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Intra Cranial EEG Activity During Dexmedetomidine Sedation.Comparing the Effects of Dexmedetomidine on the Cortical and the Sub Cortical(Hippocampus) Structures. |
Resource links provided by NLM:
Further study details as provided by University Health Network, Toronto:
| Estimated Enrollment: | 20 |
| Study Start Date: | July 2012 |
| Estimated Study Completion Date: | May 2014 |
| Estimated Primary Completion Date: | May 2014 (Final data collection date for primary outcome measure) |
Cortical and sub cortical structures will have different sensitivities to various anesthetics.The objective of this study is to look at the changes in the intracranial electroencephalographic (EEG) characteristics during dexmedetomidine sedation and to determine the differences in the EEG characteristics between cortical and subcortical structures.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Adults between 18 to 80 years of age, who are scheduled for elective removal of intracranial (surface and depth) electrodes under conscious sedation
Criteria
Inclusion Criteria:
- Adults between 18 to 80 years of age, who are scheduled for elective removal of intracranial (surface and depth) electrodes under conscious sedation
Exclusion Criteria:
- Lack of informed consent
- Hypersensitivity to dexmedetomidine
- Language barrier
- Emergency surgery
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01648959
Contacts
| Contact: Lashmikumar venkatraghavan, MD | 416-603 ext 5800 | Lashmi.Venkatraghavan@uhn.ca |
| Contact: Pirjo Manninen, MD | 416-603 ext 5118 | Prijo.Manninen@uhn.ca |
Locations
| Canada, Ontario | |
| Toronto Western Hospital,UHN. | Not yet recruiting |
| Toronto, Ontario, Canada, M5T2S8 | |
| Contact: Lashmi kumar venkatraghavan, MD 416-603 ext 5800 Lashmi.Venkatraghavan@uhn.ca | |
| Contact: Pirjo Manninen, MD 416-603 ext 5118 Pirjo.Manninen@uhn.ca | |
| Sub-Investigator: Ramamani Mariappan, MD | |
| Sub-Investigator: Taufik Valiante, MD,PhD | |
| Sub-Investigator: Pirjo Manninen, MD | |
| Principal Investigator: Lashmikumar Venkatraghavan, MD | |
Sponsors and Collaborators
University Health Network, Toronto
Investigators
| Principal Investigator: | lashmikumar venkatraghavan, MD | Assistant professor,Toronto western hospital,university health network (UHN) |
More Information
No publications provided
| Responsible Party: | University Health Network, Toronto |
| ClinicalTrials.gov Identifier: | NCT01648959 History of Changes |
| Other Study ID Numbers: | 12-0268-B |
| Study First Received: | July 13, 2012 |
| Last Updated: | July 23, 2012 |
| Health Authority: | Canada:University Health Network, Toronto.ON. |
Additional relevant MeSH terms:
|
Dexmedetomidine Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Analgesics, Non-Narcotic Analgesics |
Sensory System Agents Peripheral Nervous System Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 16, 2013